Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2020 | Lymphoma tumor microenvironment updates

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, provides an overview of our current understanding of the tumor microenvironment. While there are now a variety of strategies used to target the tumor cell, Prof Ansell asserts that the future is going to be a combination of these. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron